Drug Discovery | Novartis

Media Release
Sep 01, 2022
Novartis appoints Fiona Marshall, Ph.D., President of the Novartis Institutes for BioMedical Research as Jay Bradner, M.D., steps down from the Executive Committee of Novartis
Story
Oct 13, 2022
In neuroscience, “an inflection point in knowledge and technology”
Story
Jun 14, 2022
A shared mission to take on the “impossible” in cancer research
Story
Nov 18, 2021
The art of drug design in a technological age
Story
Nov 12, 2021
Stopping this coronavirus – and the next one
Media Release
Nov 05, 2020
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study
Media Release
Nov 06, 2020
Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS)
Media Release
Mar 30, 2021
Novartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis
Media Release
Apr 15, 2021
Novartis signs initial agreement to reserve capacity and implement the technology transfer for the production of the active pharmaceutical ingredient for Roche’s Actemra/RoActemra®
Media Release
Apr 23, 2021
Novartis to initiate SMART Phase 3b global study of Zolgensma in children up to 21 kg, building on real-world experience
Media Release
May 01, 2021
Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
Media Release
May 03, 2021
Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine